Melfalan Tillomed (Melphalan)

Melphalan works by forming covalent cross‑links between DNA strands, which blocks DNA replication and transcription. This interference triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells while sparing most normal tissues.

The dose of melphalan is individualized by the prescribing oncologist based on the specific cancer type, disease stage, patient weight, renal function and treatment protocol. No standard dose can be provided without a medical assessment.

Safety data for melphalan during pregnancy and lactation are limited, and the drug is generally considered contraindicated because of potential fetal toxicity and excretion in breast milk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Melphalan is similar to other alkylating agents such as cyclophosphamide in its DNA‑cross‑linking mechanism, but it is often preferred for certain hematologic malignancies like multiple myeloma because of its potency and dosing schedule. Toxicity profiles differ; melphalan may cause more pronounced myelosuppression, while cyclophosphamide carries a higher risk of hemorrhagic cystitis.

Melfalan Tillomed should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct light. Follow standard aseptic techniques when preparing the intravenous solution, and discard any unused portion according to local regulations.

The product is supplied for intravenous infusion. It is reconstituted with the appropriate diluent under sterile conditions and administered by a qualified healthcare professional, typically over a period of 30 minutes to several hours, depending on the prescribed regimen.

Serious risks include secondary malignancies such as therapy‑related leukemia, severe infections due to profound neutropenia, pulmonary toxicity (interstitial pneumonitis), and renal impairment or failure. Patients should be monitored closely for signs of infection, respiratory distress and changes in kidney function.

Melphalan is contraindicated in patients with known hypersensitivity to the drug or other alkylating agents, in those with severe renal or hepatic impairment, and in pregnant or nursing women unless the benefits outweigh the risks. Caution is also advised for individuals with active uncontrolled infections.